WILMINGTON, MA--(Marketwire - Feb 7, 2013) - [ Implant Sciences Corporation ] (OTCQB: [ IMSC ]), a high technology supplier of systems and sensors for homeland security and defense markets, today announced that the U.S. Patent and Trademark Office has issued the Company patent # 8,353,223, titled "Trace Particle Collection System." The patent covers a trace particle collection system that collects and removes trace particles bound to a target surface. With this issuance, [ Implant Sciences now holds 16 patents in the U.S. ]

"In trace detection, sample collection is just as important as analysis. Our research team is constantly expanding our technological capabilities," stated Implant Sciences' Vice President of Technology [ Todd Silvestri ]. "This invention is an example of Implant Sciences looking beyond traditional trace detection methods to enhance sample harvesting and transport."

"Implant Sciences continues to innovate the next generation of explosives trace detection systems," added [ Dr. Bill McGann ], Implant Sciences' Chief Operating Officer. "The recent TSA approval of our QS-B220 validates the efficacy of our groundbreaking technology and will help us solidify our position in the market."

About Implant Sciences

Implant Sciences is the leader in next generation Explosives Trace Detection (ETD) technology. In January 2013, the Company became only the third ETD manufacturer, and the sole American-owned company, to receive product approval from the US Transportation Security Administration. Implant Sciences develops, manufactures and sells sophisticated sensors and systems for Security, Safety, and Defense (SS&D) markets. The Company has developed proprietary technologies used in its commercial explosives and narcotics trace detection systems, which ship to a growing number of locations domestically and internationally. Implant Sciences' QS-H150 portable explosives trace detector has received Qualified Anti-Terrorism Technology Designation and, in addition to receiving TSA approval for air cargo screening, the Company's QS-B220 has also received a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). For further details on the Company and its products, please visit the Company's website at [ www.implantsciences.com ].

Safe Harbor Statement

This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our markets are subject to technological change and that our success depends on our ability to develop and introduce new products; that our success depends on our ability to obtain new patents and operate without infringing on the proprietary rights of others; that we may not obtain the patents we have applied for; that the validity and breadth of claims in technology patents involve complex legal and factual questions and, therefore, may be highly uncertain; that any patents we may obtain may be may be challenged and subsequently invalidated, that we may incur substantial costs in asserting our patent rights; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including its most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.